{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T20:37:14Z","timestamp":1778618234552,"version":"3.51.4"},"reference-count":47,"publisher":"BMJ","issue":"2","funder":[{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2016,2,10]]},"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Treatment options for type 2 diabetes are becoming increasingly complex with people often prescribed multiple medications, and may include both oral and injectable therapies. There is ongoing debate about which drug classes provide the optimum second-line and third-line treatment options. In the real world, patient adherence and persistence determines medication effectiveness. A better understanding of adherence may help inform the choice of second-line and third-line drug classes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>This systematic review will compare adherence and persistence rates across the different classes of medication available to people with type 2 diabetes. It will include all identified studies comparing medication adherence or persistence between two or more glucose-lowering medications in people with type 2 diabetes. Research databases (MEDLINE, EMBASE, The Cochrane Library, The Register of Controlled Trials, PsychINFO and CINAHL) will be searched for relevant articles, using a comprehensive search strategy. All identified medication trials and observational studies will be included which compare adherence or persistence across classes of diabetes medication. The characteristics and outcomes of all the included studies will be reported along with a study quality grade, assessed using the Cochrane Risk Assessment Tool. The quality of adjustment for confounders of adherence or persistence will be reported for each study. Where multiple (n \u22653) studies provide compare adherence or persistence across the same 2 medication classes, a meta-analysis will be performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>No ethics approval is required. This review and meta-analysis (where possible) will provide important information on the relative patient adherence and persistence, with the different classes of diabetes therapies. Once complete, the results will be made available by peer-reviewed publication.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>CRD42015027865.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2015-010469","type":"journal-article","created":{"date-parts":[[2016,2,29]],"date-time":"2016-02-29T22:14:56Z","timestamp":1456784096000},"page":"e010469","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":26,"title":["Systematic review of adherence rates by medication class in type 2 diabetes: a study protocol"],"prefix":"10.1136","volume":"6","author":[{"given":"Andrew","family":"McGovern","sequence":"first","affiliation":[{"name":"Section of Clinical Medicine and Aging, University of Surrey, Guildford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zayd","family":"Tippu","sequence":"additional","affiliation":[{"name":"Section of Clinical Medicine and Aging, University of Surrey, Guildford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"William","family":"Hinton","sequence":"additional","affiliation":[{"name":"Section of Clinical Medicine and Aging, University of Surrey, Guildford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neil","family":"Munro","sequence":"additional","affiliation":[{"name":"Section of Clinical Medicine and Aging, University of Surrey, Guildford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Whyte","sequence":"additional","affiliation":[{"name":"Section of Clinical Medicine and Aging, University of Surrey, Guildford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"de Lusignan","sequence":"additional","affiliation":[{"name":"Section of Clinical Medicine and Aging, University of Surrey, Guildford, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2016,2,29]]},"reference":[{"key":"2025121510500058000_6.2.e010469.1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2011.183"},{"key":"2025121510500058000_6.2.e010469.2","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-0442"},{"key":"2025121510500058000_6.2.e010469.3","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.24.3.561"},{"key":"2025121510500058000_6.2.e010469.4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.768986"},{"key":"2025121510500058000_6.2.e010469.5","doi-asserted-by":"publisher","DOI":"10.2337\/dc11-1277"},{"key":"2025121510500058000_6.2.e010469.6","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2007.01683.x"},{"key":"2025121510500058000_6.2.e010469.7","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.27.5.1218"},{"key":"2025121510500058000_6.2.e010469.8","unstructured":"National Institute for Health and Clinical Excellence. NICE guidelines [CG66]\u2014Type 2 diabetes, 2008. https:\/\/www.nice.org.uk\/guidance\/cg66"},{"key":"2025121510500058000_6.2.e010469.9","unstructured":"National Institute for Health and Clinical Excellence. NICE guidelines [CG87]\u2014Type 2 diabetes: The management of type 2 diabetes, 2009. https:\/\/www.nice.org.uk\/guidance\/cg87"},{"key":"2025121510500058000_6.2.e010469.10","unstructured":"National Institute for Health and Clinical Excellence. Dapagliflozin in combination therapy for treating type 2 diabetes: NICE technology appraisals [TA288], 2013. http:\/\/www.nice.org.uk\/Guidance\/ta288"},{"key":"2025121510500058000_6.2.e010469.11","unstructured":"Sabat\u00e9 E . Adherence to Long-Term Therapies\u2014Evidence for Action, 2003. whqlibdoc.who.int\/publications\/2003\/9241545992.pdf"},{"key":"2025121510500058000_6.2.e010469.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2011.01.019"},{"key":"2025121510500058000_6.2.e010469.13","doi-asserted-by":"publisher","DOI":"10.3111\/13696990903479199"},{"key":"2025121510500058000_6.2.e010469.14","doi-asserted-by":"crossref","unstructured":"Vermeire E , Wens J , Van Royen P , et al . Interventions for improving adherence to treatment recommendations in people with type 2 diabetes mellitus. Cochrane Database Syst Rev 2005;(2):CD003638. doi:10.1002\/14651858.CD003638.pub2","DOI":"10.1002\/14651858.CD003638.pub2"},{"key":"2025121510500058000_6.2.e010469.15","doi-asserted-by":"publisher","DOI":"10.1111\/j.1742-1241.2010.02544.x"},{"issue":"5A","key":"2025121510500058000_6.2.e010469.16","doi-asserted-by":"crossref","first-page":"27S","DOI":"10.1016\/j.amjmed.2005.04.012","article-title":"Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus","volume":"118","author":"Rubin","year":"2005","journal-title":"Am J Med"},{"key":"2025121510500058000_6.2.e010469.17","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2007.02893.x"},{"key":"2025121510500058000_6.2.e010469.18","unstructured":"World Health Organisation. Adherance to long-term therapies: Evidence for action, 2003. http:\/\/www.who.int\/chp\/knowledge\/publications\/adherence_full_report.pdf"},{"key":"2025121510500058000_6.2.e010469.19","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00213.x"},{"key":"2025121510500058000_6.2.e010469.20","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31829b1d2a"},{"key":"2025121510500058000_6.2.e010469.21","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.38875.675486.55"},{"key":"2025121510500058000_6.2.e010469.22","unstructured":"GRADE Working Group. GRADE (Grading of Recommendations Assessment, Development and Evaluation). 2015. http:\/\/www.gradeworkinggroup.org\/"},{"key":"2025121510500058000_6.2.e010469.23","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-151-4-200908180-00135"},{"key":"2025121510500058000_6.2.e010469.24","doi-asserted-by":"publisher","DOI":"10.2337\/dc14-2098"},{"key":"2025121510500058000_6.2.e010469.25","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1111\/dme.12554","article-title":"What factors influence concordance with medications? Findings from the UK Asian Diabetes study","volume":"31","author":"Lloyd","year":"2014","journal-title":"Diabet Med"},{"key":"2025121510500058000_6.2.e010469.26","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4314\/ahs.v15i2.26","article-title":"Medication adherence in type 2 diabetes patients: Study of patients in Alimosho general hospital, Igando, Lagos, Nigeria","volume":"15","author":"Awodele","year":"2015","journal-title":"Afr Health Sci"},{"key":"2025121510500058000_6.2.e010469.27","unstructured":"Fisher L , Polonsky WH , Schikman CH , et al . Emotional distress is linked to medication adherence in type 2 diabetes. Diabetes 2009;58:A478."},{"key":"2025121510500058000_6.2.e010469.28","doi-asserted-by":"publisher","DOI":"10.1016\/S1262-3636(07)70316-6"},{"key":"2025121510500058000_6.2.e010469.29","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2012.06.008"},{"key":"2025121510500058000_6.2.e010469.30","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1P442"},{"key":"2025121510500058000_6.2.e010469.31","first-page":"1071","article-title":"Race and medication adherence in medicaid enrollees with type-2 diabetes","volume":"98","author":"Shenolikar","year":"2006","journal-title":"J Natl Med Assoc"},{"key":"2025121510500058000_6.2.e010469.32","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2012.12.005"},{"key":"2025121510500058000_6.2.e010469.33","doi-asserted-by":"crossref","first-page":"A98","DOI":"10.1016\/j.jval.2011.02.551","article-title":"Treatment compliance to diabetes care: across-sectional study from Pakistan","volume":"14","author":"Parveen","year":"2011","journal-title":"Value Health"},{"key":"2025121510500058000_6.2.e010469.34","first-page":"589","article-title":"Cost sharing, adherence, and health outcomes in patients with diabetes","volume":"16","author":"Gibson","year":"2010","journal-title":"Am J Manag Care"},{"key":"2025121510500058000_6.2.e010469.35","first-page":"A75","article-title":"Treatment compliance to diabetes care: across-sectional study from Pakistan","volume":"6","author":"Khowaja","year":"2012","journal-title":"J Diabetes Sci Technol"},{"key":"2025121510500058000_6.2.e010469.36","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0032412"},{"key":"2025121510500058000_6.2.e010469.37","doi-asserted-by":"publisher","DOI":"10.2337\/dc08-1341"},{"key":"2025121510500058000_6.2.e010469.38","first-page":"95","article-title":"Predictors of nonpersistence with thiazolidinediones in patients with type 2 diabetes","volume":"29","author":"Leblond","year":"2005","journal-title":"Can J Diabetes"},{"key":"2025121510500058000_6.2.e010469.39","unstructured":"Gwadry-Sridhar F, Leslie RS, Patel B, et al. Influence of previous medication compliance on future compliance in patients with type 2 diabetes. Diabetes 2010;59:A54."},{"key":"2025121510500058000_6.2.e010469.40","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.diabres.2014.09.052","article-title":"Predictors of response to liraglutide in Japanese type 2 diabetes","volume":"106","author":"Toyoda","year":"2014","journal-title":"Diabetes Res Clin Pract"},{"key":"2025121510500058000_6.2.e010469.41","doi-asserted-by":"publisher","DOI":"10.1007\/s11606-012-2331-y"},{"key":"2025121510500058000_6.2.e010469.42","unstructured":"Gwadry-Sridhar F, Leslie RS, Patel B, et al. Understanding Predictors of Compliance in Fixed-Dose Combination vs Loose-Dose Combination Therapy for Treatment of Type 2 Diabetes. Diabetes 2010;59:A346."},{"key":"2025121510500058000_6.2.e010469.43","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e31827da5b9"},{"key":"2025121510500058000_6.2.e010469.44","unstructured":"Gravenstein S, Thompson SF, Stefanacci RG. Diabetes Treatment Patterns and Adherence among Elderly Patients from a US Managed Care Claims Database. Diabetes 2009;58:A518."},{"key":"2025121510500058000_6.2.e010469.45","doi-asserted-by":"publisher","DOI":"10.1046\/j.1464-5491.2002.00689.x"},{"key":"2025121510500058000_6.2.e010469.46","first-page":"A353","article-title":"Impact of hypoglycemia on discontinuing or down-titrating sulfonylurea among type 2 diabetes patients without insulin","volume":"17","author":"Laires","year":"2014","journal-title":"Value Health"},{"key":"2025121510500058000_6.2.e010469.47","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.5.1408"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2015-010469","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T18:50:11Z","timestamp":1765824611000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2015-010469"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2016,2,29]]},"published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1136\/bmjopen-2015-010469"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2015-010469","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]}}}